Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients
Qiaoyun Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruyun Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaobo Yu(Beijing Proteome Research Center), Le Tang(Central South University), Sheng Yang(Fujian Medical University), Guibing Wang(Beijing Proteome Research Center), Jiarui Yao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Shasha Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhishang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Dan Wang(Breast Cancer Now), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 10
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
|Nature|2017|853
Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018
|New England Journal of Medicine|2021|684
Extracellular Histones Are Mediators of Death through TLR2 and TLR4 in Mouse Fatal Liver Injury
|The Journal of Immunology|2011|522